Phase II Study of AK104 (Cadonilimab) for Recurrent Small Cell Neuroendocrine Carcinomas of the Cervix

NCT05063916 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

18

Enrollment

OTHER

Sponsor class

Conditions

Carcinomas
Cervix Cancer
Cervical Cancer

Interventions

DRUG: AK104

Sponsor

M.D. Anderson Cancer Center